title: CD5-positive diffuse large B-cell lymphoma with an unusual phenotype: Cytoplasmic CD20 (+), surface CD20 (-).
authors.forename: Norio
authors.initials: N
authors.lastname: Yokose
authors.forename: Yumiko
authors.initials: Y
authors.lastname: Shioi
authors.forename: Yuich
authors.initials: Y
authors.lastname: Sugisaki
authors.forename: Yoshiharu
authors.initials: Y
authors.lastname: Ohaki
authors.forename: Kiyoyuki
authors.initials: K
authors.lastname: Ogata
authors.forename: Kazuo
authors.initials: K
authors.lastname: Dan
mesh_terms: D000368:Aged; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20 / Q000096:biosynthesis*; D000970:Antineoplastic Agents / Q000627:therapeutic use; D018956:CD5 Antigens / Q000096:biosynthesis*; D003593:Cytoplasm / Q000378:metabolism*; D005260:Female; D005434:Flow Cytometry; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D007150:Immunohistochemistry; D016393:Lymphoma, B-Cell / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology; D010641:Phenotype; D000069283:Rituximab
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20; D000970:Antineoplastic Agents; D018956:CD5 Antigens; D000069283:Rituximab